Comparison of Biweekly and Triweekly Therapy with Docetaxel and Irinotecan for Refractory or Relapsed Advanced Non-small-cell Lung cancer
スポンサーリンク
概要
- 論文の詳細を見る
We examined which regimen of triweekly or biweekly docetaxel in combination with irinotecan demonstrates superiority of the antitumor activity and toxicity in patients with refractory or relapsed advanced non-small-cell lung cancer (NSCLC) . Patients with previously treated NSCLC of stage III or IV were eligible if they had a performance status of 2 or less, and were 75 years or younger. Patients were treated every 3 weeks with docetaxel (50 mg / m<SUP>2</SUP> on day 2) plus irinotecan (50 mg / m2 on days 1 and 8) or every 4 weeks with docetaxel (33 mg / m<SUP>2</SUP> on days 2 and 16) plus irinotecan (50 mg / m<SUP>2</SUP> on days 1 and 15) . Fifty patients were enrolled. Patient characteristics were not significantly different between the triweekly and biweekly arms. The overall response rates were 6.7 % and 14.3 %, times to progression were 2 months and 3 months, median survival times were 5 months and 8 months, and 1-year survival rates were 20% and 30% in the triweekly and biweekly arms, respectively. There were no differences in response rates, TTP, and survival between arms. In the triweekly arm, grade-3 or -4 leukopenia and diarrhea occurred more frequently than in the biweekly arm. In both arms, 2 patients had grade 3 to 4 drug-induced interstitial pneumonia but recovered after receiving steroid therapy. There were no treatment-related deaths. The biweekly arm demonstrated similar efficacy and better tolerability than the triweekly arm and can be recommended as an alternative treatment option in patients with refractory or relapsed NSCLC.
- 昭和大学・昭和医学会の論文
昭和大学・昭和医学会 | 論文
- 病理検体（ホルマリン固定パラフィン包埋組織切片）を用いた感染症遺伝子診断：結核菌Mycobacterium tuberculosis
- リンパ形質細胞性リンパ腫 / Waldenströmマクログロブリン血症
- 大学での30年間を振り返り
- 摂食・嚥下障害のリハビリテーションその包括的対応
- 原発性肝癌肝切除後の根治的治療不能残肝再発例に対するCDDP+5-FUによる肝動注療法の経験 : ―静止療法としての抗腫瘍効果と副作用―